Navigation Links
WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
Date:1/6/2009

SHANGHAI, China, Jan. 6 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced that Dr. Ge Li, the Company's Chairman and Chief Executive Officer, will present at the 27th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009, at 4:30 pm Pacific Standard Time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The Company will broadcast its presentation. The public may access the broadcast through the Investor Relations section of the Company's web site: http://www.wuxiapptec.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-215-218-5515
     Email: Ron_Aldridge@wuxiapptec.com

     Juliane Snowden
     Vice President of Investor Relations
     Burns McClellan
     Tel:   +1-212-213-0006
     Email: Jsnowden@burnsmc.com

     Web:http://www.wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmatech 2.0: Introducing Pharmatech Oncology
2. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
3. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
4. WuXi PharmaTech Announces Third Quarter 2008 Results
5. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
6. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
7. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
8. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
9. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
10. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
11. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... published their findings on what they believe could be a new and helpful ... the new research. Click here to read it now. , Biomarkers ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former senior ... the University of North Carolina Kenan-Flagler Business School effective June 27. ... Kenan-Flagler, with a focus on the school’s international efforts, leading classes and participating ...
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
Breaking Biology Technology:
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
Breaking Biology News(10 mins):